Plasma miRNA‐based signatures in CRC screening programs
Susanna Zanutto,Chiara Maura Ciniselli,Antonino Belfiore,Mara Lecchi,Enzo Masci,Gabriele Delconte,Massimo Primignani,Giulia Tosetti,Marco Dal Fante,Linda Fazzini,Aldo Airoldi,Marcello Vangeli,Francesca Turpini,Giovanni Giuseppe Rubis Passoni,Paolo Viaggi,Monica Arena,Roberta Ilaria Olimpia Motta,Anna Maria Cantù,Cristiano Crosta,Giuseppe De Roberto,Francesca Iannuzzi,Andrea Cassinotti,Valentina Dall'Olio,Laura Tizzoni,Gabriella Sozzi,Emanuele Meroni,Luigi Bisanti,Marco Alessandro Pierotti,Paolo Verderio,Manuela Gariboldi
DOI: https://doi.org/10.1002/ijc.32573
2019-08-05
International Journal of Cancer
Abstract:Colorectal cancer (CRC) screening programs help diagnose cancer precursors and early cancers and help reduce CRC mortality. However, currently recommended tests, the fecal immunochemical test (FIT) and colonoscopy, have low uptake. There is therefore a pressing need for screening strategies that are minimally invasive and consequently more acceptable to patients, most likely blood‐based, to increase early CRC identification. microRNAs (miRNAs) released from cancer cells are detectable in plasma in a remarkably stable form, making them ideal cancer biomarkers. Using plasma samples from FIT‐positive (FIT+) subjects in an Italian CRC screening program we aimed to identify plasma circulating miRNAs that detect early CRC. miRNAs were initially investigated by quantitative real‐time PCR in plasma from 60 FIT+ subjects undergoing colonoscopy at Fondazione IRCCS Istituto Nazionale dei Tumori, then tested on an internal validation cohort (IVC, 201 cases) and finally in a large multicenter prospective series (external validation cohort, EVC, 1121 cases). For each endoscopic lesion (low‐grade adenoma, LgA; high‐grade adenoma, HgA; cancer, CL) specific signatures were identified in the IVC and confirmed on the EVC. A two‐miRNA‐based signature for CL and six‐miRNA signatures for LgA and HgA were selected. In a multivariate analysis including sex and age at blood collection, the areas under the ROC curve (95%CI) of the signatures were respectively 0.644 (0.607–0.682), 0.670 (0.626–0.714) and 0.682 (0.580–0.785) for LgA, HgA and CL. A miRNA‐based test could be introduced into the FIT+ workflow of CRC screening programs so as to schedule colonoscopies only for subjects likely to benefit most.This article is protected by copyright. All rights reserved.
oncology